Sanofi Jumps As Dupixent Nears $5 Billion In Sales; Trump Drug Talks Continue
Sanofi(US:SNY) Investorsยท2025-10-24 14:06BREAKING: Stock Market Hits Record Highs After Cool CPISanofi (SNY) said Friday its anti-inflammation blockbuster, Dupixent, neared $5 billion in third-quarter sales, easily beating expectations and driving Sanofi stock closer to a breakout.This was the first time ever Dupixent sales crossed the 4 billion euro mark, Sanofi said. The drug, an eczema and asthma treatment developed with Regeneron Pharmaceuticals (REGN), generated roughly $4.88 billion in sales, according to FactSet. That topped analysts' call ...